What is it about?
This review describes development of MTBVAC from discovery to clinical development in high burden TB-endemic countries.
Featured Image
Why is it important?
MTBVAC is the first and only vaccine based on live-attenuated M. tuberculosis that has successfully entered human clinical evaluation, a historic milestone in human vaccinology.
Perspectives
MTBVAC aims to be accessible and affordable for all people. If MTBVAC successfully runs through all phases of clinical evaluation and is shown to be more effective than present BCG for pulmonary forms of TB , it could save millions of lives.
Professor Carlos Martin
University of Zaragoza
Read the Original
This page is a summary of: MTBVAC from discovery to clinical trials in tuberculosis-endemic countries, Expert Review of Vaccines, May 2017, Taylor & Francis,
DOI: 10.1080/14760584.2017.1324303.
You can read the full text:
Contributors
The following have contributed to this page
